The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease. - Trial 2014-004560-38
Access comprehensive clinical trial information for 2014-004560-38 through Pure Global AI's free database. This phase not specified trial is sponsored by Abbott Deutschland GmbH & Co. KG and is currently status unknown. The study focuses on Crohn's Disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2014-004560-38
Trial Details
EU Clinical Trials Register • 2014-004560-38
The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.
Study Focus
Sponsor & Location
Abbott Deutschland GmbH & Co. KG
Abbott Japan
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
•Ulcerative colitis or indeterminate colitis
ICD-10 Classifications
Crohn disease, unspecified
Other Crohn disease
Crohn disease of large intestine
Crohn disease [regional enteritis]
Crohn disease of small intestine
Data Source
EU Clinical Trials Register
2014-004560-38
Non-Device Trial